University of Kwa-Zulu Natal   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Durban South Africa (2004)

Organization Overview

First Clinical Trial
2004
NCT00380770
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Africa Centre for Health and Population Studies, University of KwaZullu Natal, South Africa | Doris Duke Medical Research Institute, University of KwaZulu-Natal | Nelson R Mandela School of Medicine, University of Kwazulu Natal | Nelson R Mandela School of Medicine, University of KwaZulu-Natal | UKZN/ CDRU | UKZN/ Child Development Research Unit (CDRU) | University of KwaZulu | University of KwaZulu-Natal, Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Communicable Diseases (Phase 2)

Extensively Drug-Resistant Tuberculosis (Phase 2)

HIV Infections (Phase 2)

Infections (Phase 2)

Multiple Chronic Conditions (Phase 2)

Sarcoma (Phase 4)

Sarcoma, Kaposi (Phase 4)

Tuberculosis (Phase 2)

Tuberculosis, Multidrug-Resistant (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 25